Literature DB >> 2452936

Life-threatening hyponatremia caused by vinblastine.

G Zavagli1, G Ricci, G Tataranni, G Mapelli, V Abbasciano.   

Abstract

Some days after the administration of a third bolus of ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) a patient affected by immunoblastic lymphoma underwent a neurotoxic crisis. The episode lasted 1 week and was followed by a dramatic fall in plasma sodium (104 mEq I-1), associated with a proportionally lesser decrease in plasma chloride and phosphate. Despite the lowest plasma osmolality, detectable levels of circulating ADH were present. After 36 h the hyponatremic episode improved after the infusion of hypertonic sodium chloride. Nevertheless the patient lapsed into a hypotonic coma. The urinary concentrations of the main tubular enzymes (gamma-glutamyltranspeptidase, N-acetyl-glucosaminidase, alpha-glucosidase) proved very high and successively decreased slowly. The most likely cause of such hyponatremic episode is vinblastine. The drug acted through: (a) an already known inappropriate release of ADH, and (b) a hitherto unreported tubular lesion, which impaired the reabsorption of sodium and other coupled solutes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2452936     DOI: 10.1007/bf03003183

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  13 in total

1.  Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone.

Authors:  G L Robertson; N Bhoopalam; L J Zelkowitz
Journal:  Arch Intern Med       Date:  1973-11

2.  Inappropriate secretion of antidiuretic hormone secondary to vincristine therapy.

Authors:  H O Cutting
Journal:  Am J Med       Date:  1971-08       Impact factor: 4.965

3.  Vinblastine and inappropriate ADH secretion.

Authors:  S J Ginsberg; R L Comis; A V Fitzpatrick
Journal:  N Engl J Med       Date:  1977-04-21       Impact factor: 91.245

Review 4.  Enzyme distribution along the nephron.

Authors:  W G Guder; B D Ross
Journal:  Kidney Int       Date:  1984-08       Impact factor: 10.612

5.  [Real or false hyponatremia?].

Authors:  J P Méry; A Kanfer
Journal:  Nouv Presse Med       Date:  1981-11-07

6.  The Fanconi syndrome and mechanisms of tubular transport dysfunction.

Authors:  K S Roth; J W Foreman; S Segal
Journal:  Kidney Int       Date:  1981-12       Impact factor: 10.612

7.  Syndrome of inappropriate secretion of antidiuretic hormone secondary to vinblastine overdose.

Authors:  S C Winter; G S Arbus
Journal:  Can Med Assoc J       Date:  1977-11-19       Impact factor: 8.262

8.  Effect of dietary phosphate intake on phosphate transport by isolated rat renal brush-border vesicles.

Authors:  R Stoll; R Kinne; H Murer
Journal:  Biochem J       Date:  1979-06-15       Impact factor: 3.857

9.  Paracrystalline inclusions in lysosomes of mouse kidney tubule cells induced by vinblastine and vincristine.

Authors:  J Rassat; H Robenek; H Themann
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1981

10.  Inappropriate antidiuretic hormone secretion after high dose vinblastine.

Authors:  A Antony; W A Robinson; C Roy; W Pelander; R Donohue
Journal:  J Urol       Date:  1980-05       Impact factor: 7.450

View more
  4 in total

Review 1.  Hyponatremia related to medical anticancer treatment.

Authors:  T Berghmans
Journal:  Support Care Cancer       Date:  1996-09       Impact factor: 3.603

Review 2.  Drug-induced syndrome of inappropriate antidiuretic hormone secretion. Causes, diagnosis and management.

Authors:  T Y Chan
Journal:  Drugs Aging       Date:  1997-07       Impact factor: 3.923

Review 3.  Tumor-related hyponatremia.

Authors:  Adedayo A Onitilo; Ebenezer Kio; Suhail A R Doi
Journal:  Clin Med Res       Date:  2007-12-17

4.  Hyponatremia During Induction Therapy in Distinct Pediatric Oncological Cohorts: A Retrospective Study.

Authors:  Christina Salvador; Robert Salvador; Peter Willeit; Christine Kuntner; Alexandra Haid; Thomas Müller; Gabriele Kropshofer; Roman Crazzolara
Journal:  Front Oncol       Date:  2021-10-29       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.